Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Bristol-Myers Squibb

Request full access

Biopharmaceutical medicines for patients with serious diseases

Lawrence Township, United StatesFounded 1887Biotech & Life Sciences

About Bristol-Myers Squibb

Bristol Myers Squibb discovers, develops and supplies medicines for patients with serious diseases. Its therapeutic focus includes oncology, hematology, neuroscience, immunology and cardiovascular disease.

It generates revenue primarily from medicine sales worldwide, principally to wholesalers, distributors and specialty pharmacies, with additional sales to retailers, hospitals, clinics, government agencies and patients.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 1929
Employees
38,633
Open positions
488
Dealroom signal
71.3/100
Industry
Health, Transportation
Sub-industry
Pharmaceutical
Sector
Charity, Performance Management, Tourism, Biotechnology, Drug Development, Anti-Fraud, Pay Per Result, Horizon Europe
Business model
Manufacturing
Client focus
B2B
Investment activity
131 companies, latest Jul 2026
Capital deployed
$7.5B
Preferred round
SERIES B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO DEBT✓Debt Nov 2025 $5B — Undisclosed ↗
POST IPO DEBT✓Debt Feb 2024 $13B — Undisclosed ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Bristol-Myers Squibb website traffic

Latest recorded traffic for Bristol-Myers Squibb is 790K monthly website visits, down 10.2% over the last three months. Bristol-Myers Squibb's team grew 30.9% over the past year.

Latest monthly visits790K 3-month web change-10.2% 1-year team growth+30.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

RatiotxBoston, United StatesSpecializing in the development of targeted radiotherapeutics for the treatment of cancer $280Mvaluation Beeline MedicinesStamford, United StatesPrecision therapies for autoimmune and inflammatory diseases. $1.7Bvaluation Precede BiosciencesBoston, United StatesLiquid biopsy platform profiling disease-defining transcriptional biology $254Mvaluation Link Cell TherapiesSouth San Francisco, United StatesA True CAR T Cell AND-Gate $120Mvaluation Orbital TherapeuticsSan Francisco, United StatesAims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease $1.5Bvaluation Dispatch BioPhiladelphia, United StatesCloud-powered platform for infectious disease diagnostics $864Mvaluation GlycoEraSchlieren, SwitzerlandGlycoEra’s innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications $520Mvaluation Allyx TherapeuticsNew Haven, United StatesInnovative oral therapies preserving synapses for neurodegenerative disease patients $106Mvaluation 2seventybioCambridge, United StatesImmuno-oncology cell therapy company that discovers and develops therapies used for cancer treatment $336Mvaluation Light Horse TherapeuticsSan Diego, United StatesPrecision gene editing for small molecule drug discovery $248Mvaluation Be BioCambridge, United StatesEngineering b cell medicines to improve care for serious diseases $650Mvaluation Nuvig TherapeuticsRedwood City, United StatesAdvancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function $644Mvaluation

Bristol-Myers Squibb in the Lawrence Township ecosystem

Live from Dealroom

The Bristol-Myers Squibb office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • EuroFinance

Series B and later1 investor entered at this stage

  • Carl Icahn

Other known investors5 additional known investors

  • Accelerate Okanagan
  • EW Healthcare Partners
  • Kleiner Perkins
  • Medicon Village
  • RA Capital Management
Team profiled 986 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Bristol-Myers Squibb’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.